



**CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED**

**中國神威藥業集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*(在開曼群島註冊成立之有限公司)*

**( Stock Code 股份代號 : 2877 )**

---

**NOTIFICATION LETTER 通知信函**

---

19 September 2025

Dear registered shareholder(s),

**China Shineway Pharmaceutical Group Limited (the “Company”)**

**- Notification of Publication of 2025 Interim Report (the “2025 Interim Report”)**

---

We hereby notify you that the English and Chinese versions of the 2025 Interim Report are now available on the Company’s website at [www.shineway.com.hk](http://www.shineway.com.hk) and on the HKEXnews website at [www.hkexnews.hk](http://www.hkexnews.hk).

If you want to receive the 2025 Interim Report and future Corporate Communications<sup>(Note)</sup> in printed form, you may give at least 10 days’ notice in writing served on the Company’s Hong Kong share registrar (the “Share Registrar”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong, or send an email to [ChinaShineway.ecom@computershare.com.hk](mailto:ChinaShineway.ecom@computershare.com.hk), specifying your name, address and request to receive the Corporate Communications in printed form, or contact the Customer Service Hotline of the Share Registrar at (852) 2862 8555 from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Monday to Friday (excluding public holidays) and request to receive the Corporate Communications in printed form.

Yours faithfully,

For and on behalf of

**China Shineway Pharmaceutical Group Limited**

**Lee Bun Ching Terence**

*Company Secretary*

**Note:** Corporate Communications mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

---

各位登記股東：

**中國神威藥業集團有限公司（「本公司」）**

**- 2025年中期報告（「2025年中期報告」）之發佈通知**

本公司謹此通知閣下2025年中期報告的英文及中文版本已登載於本公司網站([www.shineway.com.hk](http://www.shineway.com.hk))及香港交易所披露易網站([www.hkexnews.hk](http://www.hkexnews.hk))。

若閣下希望收取2025年中期報告及未來公司通訊<sup>(附註)</sup>的印刷版，可以提前至少10天以書面通知形式送達本公司香港辦事處股份過戶登記處（「股份過戶處」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東183號合和中心17M樓，或發送電子郵件至 [ChinaShineway.ecom@computershare.com.hk](mailto:ChinaShineway.ecom@computershare.com.hk)，並註明閣下的姓名、地址以及收取公司通訊印刷版的要求，或於週一至週五（公眾假期除外）香港時間上午9時正至下午6時正致電股份過戶處客戶服務熱線(852) 2862 8555並提出要求接收印刷版的公司通訊。

代表  
**中國神威藥業集團有限公司**  
**李品正**  
公司秘書  
謹啟

2025年9月19日

**附註：** 公司通訊指本公司為向其任何證券持有人提供資訊或提醒其採取行動而發佈或將要發佈的任何文件，包括但不限於(a)董事會報告、年度帳目連同核數師報告以及（如適用）財務摘要報告；(b)中期報告及（如適用）中期摘要報告；(c)會議通告；(d)上市文件；(e)通函；和(f)委任代表書。